Skip to main content

Oxbryta Dosage

Medically reviewed by Drugs.com. Last updated on Dec 21, 2021.

Generic name: Voxelotor 500mg
Dosage form: tablet, film coated

Recommended Dosage for Adults and Pediatric Patients 12 Years and Older

The recommended dosage of OXBRYTA is 1,500 mg orally once daily.

Recommended Dosage for Pediatric Patients 4 Years to Less Than 12 Years

For pediatric patients 4 years and older, select the appropriate product (OXBRYTA tablets or OXBRYTA tablets for oral suspension) based on patient's ability to swallow tablets and patient weight.

The recommended dosage of OXBRYTA for pediatric patients 4 years to less than 12 years is shown in Table 1.

Table 1: Recommended OXBRYTA Dosage in Pediatric Patients 4 Years to Less Than 12 Years
Body Weight Recommended Dose (once daily)
40 kg or greater 1,500 mg
20 kg to less than 40 kg 900 mg
10 kg to less than 20 kg 600 mg

Recommended Dosage for Adults and Pediatric Patients 12 Years and Older with Hepatic Impairment

The recommended dosage of OXBRYTA in adults and pediatric patients 12 years and older with severe hepatic impairment (Child Pugh C) is 1,000 mg orally once daily.

No dosage adjustment of OXBRYTA is required for patients with mild or moderate hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Recommended Dosage for Pediatric Patients 4 Years to Less Than 12 Years with Hepatic Impairment

The recommended dosage of OXBRYTA in pediatric patients 4 years to less than 12 years with severe hepatic impairment (Child Pugh C) is described in Table 2.

No dosage adjustment of OXBRYTA is required for patients with mild or moderate hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Table 2: Recommended OXBRYTA Dosage in Pediatric Patients 4 Years to Less Than 12 Years with Severe Hepatic Impairment (Child Pugh C)
Body Weight Recommended Dose (once daily)
40 kg or greater 1,000 mg (two 500 mg tablets)
or
900 mg (three 300 mg tablets for oral suspension)
20 kg to less than 40 kg 600 mg
10 kg to less than 20 kg 300 mg

Recommended Dosage of OXBRYTA for Adults and Pediatric Patients 12 Years and Older When Used with Concomitant Strong or Moderate CYP3A4 Inducers

CYP3A4 Inducers

Avoid concomitant use of strong or moderate CYP3A4 inducers with OXBRYTA [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

If concomitant use of strong CYP3A4 inducers is unavoidable, the recommended dosage of OXBRYTA is 2,500 mg orally once daily. If concomitant use of moderate CYP3A4 inducers is unavoidable, the recommended dosage of OXBRYTA is 2,000 mg orally once daily.

Recommended Dosage of OXBRYTA for Pediatric Patients 4 Years to Less Than 12 Years When Used with Concomitant Strong or Moderate CYP3A4 Inducers

CYP3A4 Inducers

Avoid concomitant use of strong or moderate CYP3A4 inducers with OXBRYTA [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. If concomitant use of strong or moderate CYP3A4 inducers is unavoidable, see Table 3 for dosage.

Table 3: OXBRYTA Recommended Dosage for Pediatric Patients 4 Years to Less Than 12 Years When Used with Concomitant Strong or Moderate CYP3A4 Inducers
Body Weight Recommended Dose (once daily)
Concomitant Use of Strong CYP3A4 Inducers Concomitant Use of Moderate CYP3A4 Inducers
40 kg or greater 2,500 mg (five 500 mg tablets)
or
2,400 mg (eight 300 mg tablets for oral suspension)
2,000 mg (four 500 mg tablets)
or
2,100 mg (seven 300 mg tablets for oral suspension)
20 kg to less than 40 kg 1,500 mg 1,200 mg
10 kg to less than 20 kg 900 mg 900 mg

Important Administration Instructions

Administer OXBRYTA orally, once daily with or without food. If a dose is missed, or not administered entirely, resume dosing the following day.

OXBRYTA may be given with or without hydroxyurea.

OXBRYTA 500 mg Tablets

Patients should swallow OXBRYTA tablets whole. Do not cut, crush, or chew the tablets.

OXBRYTA 300 mg Tablets for Oral Suspension

Patients should disperse tablets for oral suspension immediately before administration in a cup and in room temperature clear liquid (such as drinking water or clear soda) before swallowing.

Do not swallow whole, cut, crush, or chew the tablets for oral suspension.

Recommended Daily Dose Number of Tablets for Oral Suspension Minimum Recommended Volume of Clear Drink
300 mg 1 5 mL (1 teaspoon)
600 mg 2 10 mL (2 teaspoons)
900 mg 3 15 mL (3 teaspoons)
1,200 mg 4 20 mL (4 teaspoons)
1,500 mg 5 25 mL (5 teaspoons)
2,100 mg 7 35 mL (7 teaspoons)
2,400 mg 8 40 mL (8 teaspoons)
  • After the tablets start to disintegrate, swirl the contents of the cup until the tablets are dispersed, wait 1 to 5 minutes, swirl the contents of the cup again, and then orally administer the contents of the cup. The tablet(s) will not completely dissolve; there will still be small tablet clumps in the mixture.
  • Resuspend any residue left in the cup in more clear drink and administer. Repeat until no tablet residue is left in the cup.

Tablets for oral suspension may be substituted for tablets in adults and pediatric patients 12 years and older with difficulty swallowing the tablets. Use the number of tablets for oral suspension needed to achieve the recommended dose.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.